RenaCare Dialysis Clinic — Industry & Market Analysis
Disease burden and epidemiology, the kidney-replacement-therapy landscape, demand outlook, economic sizing, the competitive landscape, the regulatory environment and medical-aid tariff dynamics.
Section 3 · Business Plan
Industry & Market Analysis
Disease burden and epidemiology, the kidney-replacement-therapy landscape, demand outlook, economic sizing, the competitive landscape, the regulatory environment and medical-aid tariff dynamics.
3.1 Disease Burden & Epidemiology
Chronic kidney disease is a globally significant non-communicable
disorder that presents a disproportionately heavy burden on sub-Saharan
Africa. Systematic reviews and meta-analyses place the prevalence of CKD
across Africa at approximately 15.8% of the adult population, with
sub-Saharan Africa specifically at 17.7% — the highest regional rate in
the world. South Africa’s adult CKD prevalence is estimated at between
6% and 17%, with the heterogeneity reflecting differences in study
methodology and the absence of a comprehensive national CKD
registry.
The drivers of this burden are well established. South Africa has one
of the world’s highest combined prevalences of diabetes and hypertension
— both principal aetiologies of progressive kidney disease. Layered on
top is HIV-associated nephropathy, the APOL1 genetic variants that
predispose individuals of African ancestry to CKD, and the demographic
shift toward an older, more chronically ill population. The net effect
is a rising incident population of ESRD patients who require kidney
replacement therapy to survive.
3.2 Kidney Replacement Therapy Landscape
The South African Renal Registry (SARR), the authoritative data
source on kidney replacement therapy in South Africa, reported 9,342
prevalent patients on chronic dialysis or kidney transplantation as at
December 2022 — an overall prevalence of just 151 per million
population. Critically, 77% of these patients were treated in the
private sector despite private medical schemes covering only 14% of the
South African population. The prevalence in the private sector stood at
771 per million population, whereas the public-sector prevalence was
only 45 pmp — below the level reported for 1994.
| The access gap South Africa’s public sector dialysis prevalence of 45 pmp is among the lowest in the world. By contrast, the United States reports over 2,300 pmp and Germany more than 900 pmp. This gulf represents both a profound humanitarian challenge and a structural demand surplus that will not be closed by incumbent providers alone. |
3.3 Demand Outlook
International benchmarking studies suggest the true incidence of ESRD
in South Africa is between 170 and 200 per million population per year,
implying an incident cohort of 10,000 to 12,000 new patients annually.
Against this, the SARR records fewer than 900 patients per year actually
starting treatment. The difference — the “treatment gap” — reflects
patients who die without receiving dialysis, are refused access under
public-sector rationing protocols, or present too late for effective
intervention.
Looking forward, three factors will combine to widen demand. First,
the prevalence of Type 2 diabetes is projected to rise from
approximately 4.6 million South African adults to over 6 million by
2030. Second, hypertension prevalence among adults over 50 already
exceeds 60% and continues to climb. Third, life expectancy on
antiretroviral therapy has extended the survival of HIV-positive
patients into ages where renal complications become clinically
significant.
3.4 Economic Sizing
Annual private-sector dialysis spend in South Africa is estimated at
R4.8 billion to R5.6 billion, based on approximately 7,200 prevalent
private-sector haemodialysis patients receiving three sessions per week
at an average blended tariff of R2,400 to R2,900 per session. Discovery
Health has publicly reported that the average private-sector cost of
care for one dialysis patient is approximately R600,000 per year.
Industry analyses place the South African dialysis market on a growth
trajectory of 7% to 9% compound annual growth through 2030, materially
above underlying healthcare spend growth.
| Segment | Patients (2025E) | Annual Spend | Share |
|---|---|---|---|
| Private-sector haemodialysis | ~ 7,400 | R 4.2 bn | 73% |
| Private-sector peritoneal dialysis | ~ 1,100 | R 0.5 bn | 9% |
| Public-sector (DOH) dialysis | ~ 2,200 | R 0.9 bn | 16% |
| Transplant aftercare (private) | ~ 1,800 | R 0.1 bn | 2% |
| Total SA dialysis market | ~ 12,500 | R 5.7 bn | 100% |
3.5 Competitive Landscape
The South African private dialysis market is dominated by two
vertically integrated providers. National Renal Care (NRC), a 50/50
joint venture between Netcare and Adcock Ingram Critical Care, operates
more than 60 haemodialysis facilities nationally and is the single
largest provider. Life Healthcare’s renal dialysis division expanded
materially in May 2023 with the acquisition of Fresenius Medical Care’s
Southern African operations, gaining operational rights to 51 clinics.
B. Braun Avitum operates a smaller network of units, primarily embedded
within private hospitals. Beyond these consolidated players, a long tail
of independent nephrology practices operates small-scale dialysis units,
typically of 4 to 8 stations.
Competitive Intensity
The industry structure is best characterised as a dominant oligopoly
at the top, with meaningful white space for differentiated specialist
operators. The incumbents’ scale advantages are real — in equipment
procurement, medical aid negotiation and clinical protocol
standardisation — but are offset by three structural weaknesses: (i)
embedded cost structures inherited from hospital-group overhead
allocations; (ii) constrained ability to respond rapidly to local
referral patterns; and (iii) capital allocation priorities that favour
the hospital business over renal. Renacare’s strategy exploits each of
these gaps.
3.6 Regulatory Environment
The regulatory framework governing private dialysis provision in
South Africa is complex but stable. Facility licensing is administered
at provincial level by the Department of Health under the National
Health Act. Clinical practitioners are registered with the Health
Professions Council of South Africa (HPCSA) for nephrologists and the
South African Nursing Council (SANC) for registered nurses and clinical
technologists. Chronic renal failure is a Prescribed Minimum Benefit
under the Medical Schemes Act, meaning medical schemes are legally
required to fund its diagnosis, treatment and care.
The pending rollout of the National Health Insurance (NHI) Act,
signed into law in May 2024, introduces longer-term structural
uncertainty. However, the Act’s implementation will occur in phases over
10 to 15 years, with chronic dialysis likely to remain under the PMB
framework throughout the transition. In practice, well-capitalised
private providers are expected to continue operating largely as today
for at least the next five to seven years, with PPP-style structures
gradually expanding as NHI procurement mechanisms come online.
3.7 Medical Aid Tariff Dynamics
Chronic haemodialysis is reimbursed by South African medical schemes
at tariffs that have historically grown above headline CPI. Average
tariff per haemodialysis session in 2025 ranges from approximately
R2,400 (smaller schemes without negotiated DSP arrangements) to R3,100
(open schemes with individual arrangements). Discovery Health’s Key Care
range and the Government Employees Medical Scheme (GEMS) have materially
increased their DSP networks in the past three years, generally at
tariffs around 15% below open-scheme rates in exchange for patient
volume. The Council for Medical Schemes has guided tariff increases of
4.4% for 2025, though private-medical inflation in practice has
consistently run 2 to 3 percentage points higher.
Confidential — this business plan is provided to prospective investors and lenders for evaluation purposes only and may not be reproduced or distributed without the written consent of RenaCare Dialysis Clinic (Pty) Ltd.